The Global Non-Opioid Pain Treatment Market is expected to grow at an annual rate of about 8% during the period from 2024 to 2031. The market is projected to increase from around USD 44.39 billion in 2024 to about USD 91.74 billion by 2031.

This growth is fueled by the rising number of chronic pain conditions like arthritis, cancer pain, and neuropathic pain, along with a greater awareness of the risks tied to opioid use. New developments in non-opioid drug formulations, including NSAIDs, acetaminophen, local anesthetics, and new therapies such as cannabinoids, are driving market growth. Additionally, the push to reduce opioid prescriptions, the introduction of innovative delivery systems, and increased investment in research and development are helping the market grow globally.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://www.datamintelligence.com/download-sample/non-opioid-pain-treatment-market?ram

Key Developments:

United States: Non-Opioid Pain Treatment Market

- October 2025: Semnur Pharmaceuticals completed a $2.5 billion merger with Denali Capital Acquisition Corp to advance Semdexa, its injectable corticosteroid gel for moderate to severe sciatica pain, moving closer to commercialization.

- September 2025: Pfizer expanded its non-opioid pain relief portfolio with a new selective COX-2 inhibitor aimed at reducing gastrointestinal side effects often seen with NSAIDs.

- August 2025: Eli Lilly shared early phase results from clinical trials of a new non-opioid pain candidate for neuropathic pain, targeting patients with opioid intolerance.

- July 2025: Johnson & Johnson released new over-the-counter topical analgesic formulations that incorporate advanced delivery technologies for better skin absorption and longer-lasting pain relief.

Japan: Non-Opioid Pain Treatment Market

- October 2025: Takeda Pharmaceutical began clinical trials for a new non-opioid treatment that combines anti-inflammatory effects with nerve growth modulation, aimed at chronic joint pain.

- September 2025: Astellas Pharma launched a national awareness campaign promoting safer non-opioid pain management solutions in collaboration with leading healthcare providers.

- August 2025: Chugai Pharmaceutical Co., Ltd. partnered with tech startups to test digital health platforms that integrate personalized non-opioid pain treatment plans.

- July 2025: Otsuka Pharmaceutical created an extended-release version of acetaminophen for chronic musculoskeletal pain, enhancing patient adherence and effectiveness.

Recent Mergers and Acquisitions (M&A):

United States: Non-Opioid Pain Treatment Market

- October 2025: Semnur Pharmaceuticals' merger with Denali Capital Acquisition Corp provided significant funding for developing and commercializing injectable non-opioid pain treatments.

- August 2025: Pfizer purchased a biotechnology startup focused on new non-opioid pain relief compounds to strengthen its research and development pipeline for safer pain management options.

Japan: Non-Opioid Pain Treatment Market

- October 2025: Takeda Pharmaceutical merged with a regional company specializing in non-opioid pain treatments to speed up the development of next-generation pain relief drugs for Asian markets.

- August 2025: Astellas Pharma formed a strategic partnership with a digital health firm to improve patient adherence and monitoring in chronic non-opioid pain treatment programs.

Key Players:

=> Aphria Inc., Aurora, Bedrocan, Canopy Growth Corp., Cara Therapeutics, Centrexion Therapeutics, Cronos Group, GW Pharmaceuticals, Medical Marijuana Inc., Medropharm GmbH, Panag Pharma Inc., Tilray, US Worldmeds LLC, and Vanway

Market Dynamics and Growth Drivers:

- Rising Incidence of Chronic Pain Conditions: The growth in chronic pain conditions like arthritis, fibromyalgia, and diabetes is increasing the demand for effective pain management solutions.

- Growing Awareness and Preference for Non-Opioid Alternatives: More patients and healthcare providers are becoming aware of the risks associated with opioid use, leading to a preference for non-opioid pain management options.

- Advancements in Pharmaceutical Research and Development: Ongoing research efforts are resulting in the discovery and approval of new non-opioid pain medications, which expand treatment options for patients.

- Supportive Regulatory Initiatives: Regulatory agencies are guiding and supporting the development and approval of non-opioid pain treatments, helping to facilitate market growth.

- Expansion of Pain Management Clinics and Services: The rise of specialized pain management clinics and services is increasing patient access to non-opioid pain treatment solutions.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=non-opioid-pain-treatment-market?ram

Growth Forecast Projected:

The Global Non-Opioid Pain Treatment Market is expected to rise significantly between 2024 and 2031. In 2023, the market is steadily growing, and with increasing strategies from key players, it is anticipated to advance over the projected period.

Research Process:

The Global Non-Opioid Pain Treatment Market research report incorporates both primary and secondary data sources. During the research, many factors affecting the industry were evaluated, including government regulations, market conditions, competitive levels, historical data, market status, technological advancements, future developments in related fields, as well as market volatility, prospects, challenges, and potential barriers.

Key Segments:

➥ By Drug Type: NSAIDs, Corticosteroids, Medical Cannabis Treatment, Menthol-Containing Treatment, Others

➥ By Application: Orthopedic and Musculoskeletal Pain, Neuropathic Pain, Cancer Pain, Other Pain

Contact Us -

Company Name: DataM Intelligence

Contact Person: Sai Kiran

Email: Sai.k@datamintelligence.com

Phone: +1 877 441 4866

Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.